VIKING THERAPEUTICS INC (VKTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.87+2.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VKTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 100% of the last 2 guided quarters · 0.0% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue enrollment and progress of Phase 3 VANQUISH-1 and VANQUISH-2 trials for subcutaneous VK2735 and initiate Phase 3 oral VK2735 trial in Q4 2026.
Stated as a priority in 2 of last 2 quarters. The Phase 3 VANQUISH-1 and VANQUISH-2 trials for subcutaneous VK2735 are fully enrolled with approximately 4,500 and 1,000 patients respectively. The oral Phase 3 VK2735 trial is planned to start in Q4 2026. Management is delivering on enrollment and trial progression as planned.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing; Oral Phase 3 VK2735 Trial Initiation Expected 4Q26”
“VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled; Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26”
Advance VK3019, a dual amylin and calcitonin receptor agonist, into clinical development with Phase 1 trial initiated in Q2 2026.
Stated as a priority in 2 of last 2 quarters. The IND for VK3019 was filed in Q1 2026 and the Phase 1 trial was initiated in Q2 2026 as planned. Management is delivering on advancing this novel obesity treatment candidate into clinical development.
“Phase 1 Study of Amylin Agonist VK3019 Underway; IND Filed in Q1 2026”
“IND Filed for Novel Amylin Agonist VK3019; Phase 1 Trial Initiation Planned for 2Q26”
Manage operating expenses carefully while increasing investment in clinical studies and infrastructure to support pipeline advancement.
Stated as a priority in 2 of last 2 quarters. R&D expenses increased significantly from $41.4M in 2025-Q1 to $150.2M in 2026-Q1 and from $60.2M in 2025-Q2 to $115.8M in 2026-Q2, reflecting increased clinical and infrastructure investment. Management emphasizes fiscal responsibility amid this spending, indicating ongoing cost discipline with expanded operations.
“Carefully expanding internal infrastructure adding capabilities to maximize opportunities ahead.”
“Executing a fiscally responsible and timely strategic expansion plan that ensures Viking has the partnerships, vendors and in-house expertise required.”
Conduct Phase 1 dose-ranging study of VK2735 maintenance dosing regimens and expect to report results in Q3 2026.
Stated as a priority in 2 of last 2 quarters. The Phase 1 maintenance dosing study for VK2735 is ongoing with enrollment completed in January 2026 and data expected in Q3 2026. Management is delivering on study progress and timeline adherence.
“VK2735 Maintenance Dosing Study Data Expected 3Q26; exploring weekly, every other week, and monthly dosing.”
“VK2735 Maintenance Dosing Study Ongoing; Data Expected 3Q26”
Over the trailing year it converted 0.74x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
3 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.